DUBLIN–(BUSINESS WIRE)–The “Fibroblast
Growth Factor Receptor 4 (FGFR4) Inhibitors – Pipeline Insights, 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.
The report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across
Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors development.
The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental
Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.
Scope of the Report
-
The report provides a snapshot of the pipeline development for
Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -
The report covers pipeline activity across the complete product
development cycle i.e. clinical, pre-clinical and discovery stages for
Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -
The report provides pipeline product profiles which includes product
description, developmental activities, licensors & collaborators and
chemical information -
Provides pipeline assessment by monotherapy and combination therapy
products, stage of development, route of administration, and molecule
type for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -
The report also covers the dormant and discontinued pipeline projects
related to Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
Reasons to Buy
-
Establish comprehensive understanding of the pipeline activity across
this Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors to
formulate effective R&D strategies -
Gather information of the emerging competitors having potentially
lucrative portfolio in this space and create effective counter
strategies to gain competitive advantage -
Identify the relationship between the drugs and use it for target
finding, drug repurposing, and precision medicine -
Plot corrective measures for pipeline projects by understanding the
pipeline depth and focus of Fibroblast Growth Factor Receptor 4
(FGFR4) Inhibitors therapeutics -
Devise in licensing and out licensing strategies by identifying
prospective partners with the most attractive projects to enhance and
expand business potential and scope -
Modify the therapeutic portfolio by identifying inactive projects and
understanding the factors that might have halted their progress
Key Topics Covered
1. Report Introduction
2. Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
-Pipeline Insights, 2019 Overview
3. Pipeline Therapeutics
-
An Overview of Pipeline Products for Fibroblast Growth Factor Receptor
4 (FGFR4) Inhibitors -Pipeline Insights, 2019
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
- Product Development Activities
Companies Mentioned
- Ionis Pharmaceutical
- H3 Biomedicine Inc.
- Daiichi Sankyo Inc.
- Blueprint Medicines Corp.
- Incyte Corporation
- Genosco
- AstraZeneca
- Eli Lilly
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2u4k5e
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs